RxSight, Inc. (RXST) News
Filter RXST News Items
RXST News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RXST News Highlights
- For RXST, its 30 day story count is now at 9.
- Over the past 15 days, the trend for RXST's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- AGE, DECK and EYE are the most mentioned tickers in articles about RXST.
Latest RXST News From Around the Web
Below are the latest news stories about RXSIGHT INC that investors may wish to consider to help them evaluate RXST as an investment opportunity.
Rxsight (RXST) Investor Presentation - SlideshowThe following slide deck was published by RxSight, Inc. |
RxSight guides Q4 revenue growth of 91% Y/YMedical technology company RxSight (RXST) expects Q4 revenue of ~$16.1M, representing growth of around 91% Y/Y |
Investing in RxSight (NASDAQ:RXST) a year ago would have delivered you a 12% gainIf you want to compound wealth in the stock market, you can do so by buying an index fund. But you can significantly... |
RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial and Operational ResultsALISO VIEJO, Calif., Jan. 08, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2022. |
Mediaplanet and RxSight® Team Up to Bring Awareness to Eye Health and Vision CareLeading medical technology company, RxSight®, joins Mediaplanet''s Vision Care campaign to shed light on breakthrough technology for cataract patients ALISO VIEJO, Calif. , Jan. 6, 2023 /PRNewswire-PRWeb/ -- Approximately 32 million Americans reported experiencing vision loss in 2018, and more than half of all Americans will have cataracts by age 80. Luckily, cataract surgery is effective and safe, with 90% of patients reporting improved vision. However, many people report that their post-surgery vision isn''t as good as they''d hoped. The Light Adjustable LensTM (LAL®) by RxSight® is aiming to fix this dilemma by allowing you to test drive your post-cataract surgery vision. "What''s unique about the Light Adjustable Lens is that the adjustment is done post-op," notes Dr. Dan Durrie , r... |
RxSight, Inc. (NASDAQ:RXST) Q3 2022 Earnings Call TranscriptRxSight, Inc. (NASDAQ:RXST) Q3 2022 Earnings Call Transcript November 7, 2022 RxSight, Inc. beats earnings expectations. Reported EPS is $-0.61, expectations were $-0.71. Operator: Hello and thank you for standing by. Welcome to the RxSight Third Quarter 2022 Earnings Conference Call. At this time, all the participants are in a listen-only mode. After the speakers’ […] |
RxSight, Inc. to Present at the J.P. Morgan Healthcare ConferenceALISO VIEJO, Calif., Dec. 28, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced plans to participate in the upcoming J.P. Morgan Healthcare Conference. |
Has IntraCellular Therapies (ITCI) Outpaced Other Medical Stocks This Year?Here is how Intra-Cellular Therapies (ITCI) and RxSight, Inc. (RXST) have performed compared to their sector so far this year. |
RxSight falls after Well Fargo cuts rating to equal weight on economic downturnRxSight (RXST) is trading ~5% lower after Wells Fargo downgraded to equal weight from overweightWells Fargo analyst Larry Biegelsen believes demand for RxSight''s light adjustable… |
Is RxSight (RXST) Stock Outpacing Its Medical Peers This Year?Here is how RxSight, Inc. (RXST) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year. |